NDRA · ENDRA Life Sciences Inc. · Insider Trading

Holdings include unvested restricted stock units ("RSUs").

Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026.

Holdings include unvested restricted stock units ("RSUs").

Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026.

Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027.

Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027.

Includes unvested RSUs.

Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027.

Includes unvested RSUs.

Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027.

Holdings include unvested restricted stock units ("RSUs").

Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2026.

The shares of Common Stock and Warrants were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended.

Each share of Common Stock was purchased together with Warrants exercisable for two shares of Common Stock.

Includes unvested restricted stock units.

The shares of Common Stock and Warrants were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended.

Each share of Common Stock was purchased together with Warrants exercisable for two shares of Common Stock.

Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026.

Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026.

Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026.

This Statement is filed jointly by UBS Group AG for the benefit and on behalf of UBS Securities LLC and UBS Financial Services Inc., a wholly owned subsidiary of UBS Group.

This Form 4 Amendment is being filed to correct and replace the original Form 4 filed on August 29, 2024. Subsequent to the date of first filing, the Reporting Person confirmed directly with the Issuer that, due to certain warrant exercises effected on August 27, 2024, the total outstanding common shares issued by ENDRA Life Sciences as of August 27, 2024 was 16,932,593 shares. When taking the revised share count into consideration, the Reporting Person determined it never beneficially owned more than 10% of ENDRA shares. Therefore the Form 4 previously filed by the Reporting Person was erroneous and unnecessary

This Statement is filed jointly by UBS Group AG for the benefit and on behalf of UBS Securities LLC and UBS Financial Services Inc., a wholly owned subsidiary of UBS Group

Represents a stock option award granted on January 2, 2024 pursuant to the Issuer's Non-Employee Director Compensation Policy.

This stock option award becomes exercisable in three equal annual installments beginning January 2, 2025.

Represents a stock option award granted on January 2, 2024 pursuant to the Issuer's Non-Employee Director Compensation Policy.

This stock option award becomes exercisable in three equal annual installments beginning January 2, 2025.

Represents a stock option award granted on January 2, 2024 pursuant to the Issuer's Non-Employee Director Compensation Policy.

This stock option award becomes exercisable in three equal annual installments beginning January 2, 2025.

Represents a stock option award granted on January 2, 2024 pursuant to the Issuer's Non-Employee Director Compensation Policy.

This stock option award becomes exercisable in three equal annual installments beginning January 2, 2025.

Represents shares purchased in the Registrant's underwritten public offering that closed May 2, 2023 (the "Offering").

The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock was $2.41 per set of securities, yielding an effective price of $1.20 per share and $0.01 per warrant in the Offering.

The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock was $2.41 per set of securities, yielding an effective price of $1.20 per share and $0.01 per warrant in the Offering.

Represents warrants purchased in the Offering. The warrants were offered and sold at the rate of one warrant to purchase one share for every two shares of common stock purchased in the Offering.

This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024.

This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024.

This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024.

This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024.

This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024.

This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024.

This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024.

On December 9, 2022, the Issuer effected a 1-for-20 reverse stock split (the "Reverse Stock Split") of its outstanding Common Stock. The number of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1911 to $0.1963, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.

This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023.

This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023.

This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023.

This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023.

This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023.

This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023.

This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023.

This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023.

Represents a stock option award granted on January 3, 2022 pursuant to the Issuer's Non-Employee Director Compensation Policy.

Represents a stock option award granted on January 3, 2022 pursuant to the Issuer's Non-Employee Director Compensation Policy.

Represents a stock option award granted on January 3, 2022 pursuant to the Issuer's Non-Employee Director Compensation Policy.

Represents a stock option award granted on January 3, 2022 pursuant to the Issuer's Non-Employee Director Compensation Policy.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.81 to $1.84, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.